Breaking News

Coherus Biosciences Names Commercial Strategy SVP

April 28, 2014

Fleming brings more than 25 years of biopharma experience

Michael A. Fleming has been appointed senior vice president of Commercial Strategy at Coherus Biosciences.
 
Mr. Fleming has more than 25 years of experience in the biopharma industry, including senior leadership and executive management roles with Elan Corp., Nuvelo, Inc., Genentech, GlaxoSmithKline, SmithKline Beecham, and inVentiv Health. He has been instrumental in the launch, commercialization, and business development of numerous products in various therapeutic areas including HIV, infectious diseases, diabetes, CNS, multiple sclerosis, cardiovascular, and oncology.
 
"Michael is a vital addition to the Coherus team at this time," said Denny Lanfear, president and chief executive officer of Coherus. "Our pipeline is now sufficiently advanced to begin evaluating our strategic options for commercialization. Michael's experience in building commercial operations and his knowledge of markets and health systems are of immediate importance. He will play a key role in defining strategies that effectively maximize the commercial potential of our products."
blog comments powered by Disqus
  • CMO Systems

    CMO Systems

    Philip K. Burns, CRO Consulting||April 5, 2016
    A CMO system includes four aspects of the product lifecycle: regulatory, technical, compliance, and operations.

  • Injectables: The New Oral?

    Injectables: The New Oral?

    Tugrul Kararli, Kurt Sedo, Josef Bossart, PharmaCircle LLC||April 5, 2016
    The growth trend of injectables continues across the pharma landscape.

  • Biopharmaceutical Contract Manufacturing Contract Negotiations

    Biopharmaceutical Contract Manufacturing Contract Negotiations

    William Downey, HighTech Business Decisions||April 5, 2016
    Navigating the complexities of supply agreements.